133 related articles for article (PubMed ID: 12141068)
1. Serum placental protein 14: a novel marker of selective oestrogen receptor modulator action on the postmenopausal endometrium.
Tankó LB; Warming L; Bagger YZ; Byrjalsen I; Jensen S; Christiansen C
Biomarkers; 2002; 7(3):257-66. PubMed ID: 12141068
[TBL] [Abstract][Full Text] [Related]
2. Placental protein 14 (PP14) does not predict endometrial status under hormone replacement therapy.
Haenggi W; Bersinger NA; Altermatt HJ; Birkhaeuser MH
Gynecol Endocrinol; 1997 Feb; 11(1):51-7. PubMed ID: 9086340
[TBL] [Abstract][Full Text] [Related]
3. Associated response in bone mineral density and atherogenic lipid profile during treatment with two different selective estrogen receptor modulators: levormeloxifene and raloxifene.
Bloch-Thomsen A; Silvestri S; Christiansen C; Bjarnason NH
Climacteric; 2003 Jun; 6(2):159-67. PubMed ID: 12841887
[TBL] [Abstract][Full Text] [Related]
4. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium.
Goldstein SR; Scheele WH; Rajagopalan SK; Wilkie JL; Walsh BW; Parsons AK
Obstet Gynecol; 2000 Jan; 95(1):95-103. PubMed ID: 10636510
[TBL] [Abstract][Full Text] [Related]
5. Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapy.
Byrjalsen I; Thormann L; Meinecke B; Riis BJ; Christiansen C
Hum Reprod; 1992 Sep; 7(8):1042-7. PubMed ID: 1400926
[TBL] [Abstract][Full Text] [Related]
6. Clinical applications of serum placental protein 14 (PP14) measurement in the IVF-ET cycle.
Suzuki Y; Sugiyama R; Fukumine N; Usuda S; Itoh H; Isaka K; Takayama M; Teisner B
J Obstet Gynaecol Res; 2000 Aug; 26(4):295-302. PubMed ID: 11049241
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized controlled study comparing two doses of gestodene in cyclic combined HRT preparations on endometrial physiology.
Okon MA; Lee S; Laird SM; Li TC
Hum Reprod; 2001 Jun; 16(6):1244-50. PubMed ID: 11387299
[TBL] [Abstract][Full Text] [Related]
8. The measurement of secretory endometrial protein PP14 in serum from postmenopausal women receiving unopposed estrogen or continuously combined estrogen/progestogen.
Byrjalsen I; Riis BJ; Christiansen C
Gynecol Endocrinol; 1989 Jun; 3(2):143-52. PubMed ID: 2816479
[TBL] [Abstract][Full Text] [Related]
9. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
10. Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.
Cohen FJ; Watts S; Shah A; Akers R; Plouffe L
Obstet Gynecol; 2000 Jan; 95(1):104-10. PubMed ID: 10636511
[TBL] [Abstract][Full Text] [Related]
11. Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study.
de Azevedo GD; do Prado MF; Ferriani RA; dos Reis RM; Berezowski AT; Ribeiro TF; Silva E; de Oliveira Maranhão TM; Silva de Sá MF
Maturitas; 2004 Mar; 47(3):195-200. PubMed ID: 15036489
[TBL] [Abstract][Full Text] [Related]
12. Transvaginal sonographic monitoring of the uterine effects of raloxifene and a continuous combined replacement therapy in postmenopausal women.
Christodoulacos G; Panoulis C; Botsis D; Rizos D; Kassanos D; Creatsas G
Maturitas; 2002 May; 42(1):77-84. PubMed ID: 12020983
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of a SERM (Levormeloxifene). Safety parameters and bone mineral density 12 months after treatment withdrawal.
Warming L; Christoffersen C; Riis BJ; Stakkestad JA; Delmas PD; Christiansen C
Maturitas; 2003 Mar; 44(3):189-99. PubMed ID: 12648882
[TBL] [Abstract][Full Text] [Related]
14. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of 'period-free' hormone replacement therapy.
Okon MA; Lee S; Laird SM; Li TC
Hum Reprod; 1998 Aug; 13(8):2261-5. PubMed ID: 9756307
[TBL] [Abstract][Full Text] [Related]
15. Transvaginal color Doppler sonographic evaluation of the uterus in postmenopausal women on daily raloxifene therapy.
Chittacharoen A; Theppisai U; Manonai J
Climacteric; 2002 Jun; 5(2):156-9. PubMed ID: 12051111
[TBL] [Abstract][Full Text] [Related]
16. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women.
Archer DF; Pinkerton JV; Utian WH; Menegoci JC; de Villiers TJ; Yuen CK; Levine AB; Chines AA; Constantine GD
Menopause; 2009; 16(6):1109-15. PubMed ID: 19543129
[TBL] [Abstract][Full Text] [Related]
17. Circulating concentrations of placenta protein 14 during the natural menstrual cycle in women significantly reflect endometrial receptivity to implantation and pregnancy during successive assisted reproduction cycles.
Westergaard LG; Wiberg N; Andersen CY; Laursen SB; Kliem A; Westergaard JG; Teisner B
Hum Reprod; 1998 Sep; 13(9):2612-9. PubMed ID: 9806294
[TBL] [Abstract][Full Text] [Related]
18. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women.
Ronkin S; Northington R; Baracat E; Nunes MG; Archer DF; Constantine G; Pickar JH
Obstet Gynecol; 2005 Jun; 105(6):1397-404. PubMed ID: 15932835
[TBL] [Abstract][Full Text] [Related]
19. Micronized oral progesterone increases the circulating level of endometrial secretory PP14/beta-lactoglobulin homologue.
Seppälä M; Rönnberg L; Karonen SL; Kauppila A
Hum Reprod; 1987 Aug; 2(6):453-5. PubMed ID: 3312283
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study.
Palacios S; de Villiers TJ; Nardone Fde C; Levine AB; Williams R; Hines T; Mirkin S; Chines AA;
Maturitas; 2013 Sep; 76(1):81-7. PubMed ID: 23871271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
